Goldman Sachs reinstated coverage of Esperion (ESPR) with a Neutral rating and $4 price target Post the label expansion, Nexletol and Nexlizet uptake has started to pick up but key opinion leader feedback remains mixed, the analyst tells investors in a research note. The firm says investor focus has likely returned to Esperion’s commercial prospects and fundamentals, which it views balanced at the current share price.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- Esperion initiated with an Overweight at Cantor Fitzgerald
- Esperion entered into licensing agreement with Neopharm Israel
- Esperion selloff continues following competitor data from NewAmsterdam
- Biotech Alert: Searches spiking for these stocks today
- Esperion announces new drug submissions in Canada for NEXLETOL